QUANTEL (EPA:QUA) Quantel signs a distribution agreement with US-based National Biological

Transparency directive : regulatory news

14/10/2009 17:35

Press release

Les UIis (France) October 14th, 2009

National Biological to market Quantel`s 308 Excimer System for Psoriasis and
Vitiligo in the United States

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers,
announced today that it has entered into a Distribution Agreement with National
Biological, a leading researcher and developer of light-based systems for
medical and cosmetic treatments, for Quantel`s 308 Excimer System for
monochromatic UVB treatment of psoriasis and vitiligo in the United States.

Monochromatic UVB Therapy

The 308 Excimer System was developed by Quantel Derma, GmbH based in Erlangen,
Germany. Its monochromatic light is equivalent to an excimer laser, with
comparable clinical results. The 308 Excimer System is portable, efficient and
has no consumables.

National Biological`s Chief Executive Officer, Ken Oif commented, "The
Quantel 308 targeted phototherapy System provides the best solution for the tens
of thousands of patients who require localized treatment for psoriasis,
vitiligo, and other skin diseases which are responsive to UV light. It is proven
to be very effective and extremely easy to use. National Biological is very
pleased to be able to provide Dermatologists with the best value of any targeted
phototherapy system. "

Exclusivity in the United States

The 308 Excimer System will be exclusively marketed by National Biological in
the United States. National Biological will provide the Marketing, Sales,
Clinical and Service support.

Alain de Salaberry, Quantel`s Président Directeur Général said: "Its
strong sales organization and its experience with UVB devices make National
Biological an ideal partner for the marketing of Quantel`s 308 Excimer
System"

ABOUT THE QUANTEL GROUP

Founded in 1970, the QUANTEL Group has over the last 10 years established itself
as one of the world's leading specialists for scientific (research laboratories,
universities), industrial (micromachining, metrics, military) and medical
(ophthalmology, dermatology) laser technologies.

ABOUT NATION BIOLOGICAL CORPORATION, INC.

National Biological was founded in 1967 by a pharmacist who understood clearly
that UV phototherapy provided a safer and more effective treatment than drugs
for severe or chronic psoriasis, eczema, vitiligo and other skin conditions.
Over the nearly 40 years since then, National Biological has become widely
recognized among doctors and patients alike as the world leader in our field,
consistently providing innovation, manufacture, and distribution of phototherapy
equipment.

Quantel is listed on NYSE Euronext (compartiment C)

FR0000038242 - QUA

www.quantel-laser.com

Alain de SALABERRY                   Mark Friedman
Président Directeur                  Général President
T : +33 1 69 29 17 00                T : +1-216-831-0600
info@quantel.fr                      Info@PhototherapyExperts.com

Stefan SCHULZE
CEO Quantel Derma GmbH
T : +49 9131 9408810
info@quantel-derma.com

QUANTEL's latest news

26/01/2024 16:10

QUANTEL (EPA:QUA) Quantel signs a distribution agreement with US-based National Biological

Transparency directive : regulatory news

QUANTEL's latest news

Other stories